Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Resverlogix Corp
Bullboard Posts
User Avatar Image
(6)
•••
Comment by BearDownAZon Oct 09, 2015 10:36am
107 Views
Post# 24178978

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Tomorrow is Friday,,,,wink,,wink.. :o) ,,,,!!

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Tomorrow is Friday,,,,wink,,wink.. :o) ,,,,!!I clicked the report abuse button for "cutthewabs" and that same day he/she was banned. I'm sure there are others besides the two of us who reported cutthewabs. In my almost 3 years on stockhouse on the BTI and RVX boards, I've never seen anyone as disrespectful as "princeofcut" and "cutthewabs." I encourage all Stockhouse users to click the "report abuse"  button in the future if this type of posting surfaces again from current or future posters. Trussel, you are clearly offended by the action of us "rats". However, all of princeofcut's and cutthewabs' posts are public and out in the open. No secrets. We all know the twisted truths, falsehoods, disrespect, insults, bullying that he/she conveyed. Princeofcut/cutthewabs brought this upon his/herself. We simply cleaned house......Stockhouse that is. 

Best,

BearDownAZ
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities